This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McSharry, J. J.
Right arrow Articles by Drusano, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McSharry, J. J.
Right arrow Articles by Drusano, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2925-2927, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2925-2927.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Susceptibilities of Human Cytomegalovirus Clinical Isolates to BAY38-4766, BAY43-9695, and Ganciclovir

James J. McSharry,1,* Ann McDonough,1 Betty Olson,1 Sabine Hallenberger,2 Juergen Reefschlaeger,2 Wolfgang Bender,3 and George L. Drusano1

Center for Immunology and Microbial Diseases and the Clinical Research Institute, Albany Medical College, Albany, New York 12208,1 and Departments of Antiinfectives2 and Medicinal Chemistry,3 Pharmaceutical Research Center, Bayer AG, D-42096 Wuppertal, Germany

Received 19 March 2001/Returned for modification 21 May 2001/Accepted 11 July 2001

BAY38-4766 and BAY43-9695 are nonnucleosidic compounds with activities against human cytomegalovirus (HCMV). Two phenotypic assays were used to determine the drug susceptibilities of 36 HCMV clinical isolates to the BAY compounds and ganciclovir. Using either assay, both BAY compounds at a concentration of approximately 1 µM inhibited the replication of all 36 HCMV clinical isolates, including 11 ganciclovir-resistant clinical isolates, by 50%.

* Corresponding author. Mailing address: Center for Immunology and Microbial Diseases, Mail Code 151, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-5174. Fax: (518) 262-5748. E-mail: mcsharj{at}mail.amc.edu.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2925-2927, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2925-2927.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gilbert, C., Boivin, G. (2005). Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob. Agents Chemother. 49: 873-883 [Full Text]  
  • McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L. (2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI 11: 21-28 [Abstract] [Full Text]  
  • Razonable, R. R., Paya, C. V., Smith, T. F. (2002). Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients. J. Clin. Microbiol. 40: 746-752 [Full Text]  
  • Reefschlaeger, J., Bender, W., Hallenberger, S., Weber, O., Eckenberg, P., Goldmann, S., Haerter, M., Buerger, I., Trappe, J., Herrington, J. A., Haebich, D., Ruebsamen-Waigmann, H. (2001). Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 48: 757-767 [Abstract] [Full Text]  
  • McSharry, J. J., McDonough, A., Olson, B., Talarico, C., Davis, M., Biron, K. K. (2001). Inhibition of Ganciclovir-Susceptible and -Resistant Human Cytomegalovirus Clinical Isolates by the Benzimidazole L-Riboside 1263W94. CVI 8: 1279-1281 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»